The Global Drug Survey 2020 is a large online survey on drug use collected between November 2019 and February 2020.
Positive changes were observed across all 17 outcome items, with the strongest benefits on items related to insight and mood. Negative effects were reported by 22.5% of respondents.
High intensity of psychedelic experience, seeking advice before treatment, treating with psilocybin mushrooms and treating post-traumatic stress disorder were associated with higher scores on the self-treatment outcome scale after averaging values across all 17 items.
Younger age, high intensity of experience and treating with LSD were associated with increased number of negative outcomes.
Read moreBetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that findings from a study on its lead candidate BETR-001 (2-bromo-LSD) titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders” has been published in the peer-reviewed journal of Cell Report.
What do you think?
Read moreNew research finds LSD effective in decreasing anxiety and depression.
Researchers report “effects were maximal 2 weeks after the second LSD session and sustained up to 16 weeks.”
Read moreIs it all hype or is there genuine hope for therapeutic application of microdosing?
There’s certainly plenty of ‘conflicting’ information or results available from studies of different methodologies. Here, we begin with an overview of what microdosing is, who does it, and for what purposes. We then review available evidence and summarize benefits and risks of microdosing. Finally, we get more practical and discuss microdosing regimens, measurement of accurate dosing, and ‘set and setting’ consideration to microdosing.
Read more